Journal of
Cancer Research and Experimental Oncology

  • Abbreviation: J. Cancer Res. Exp. Oncol.
  • Language: English
  • ISSN: 2141-2243
  • DOI: 10.5897/JCREO
  • Start Year: 2009
  • Published Articles: 58

Short Communication

Long term remission with 6-Mercaptopurine in refractory Evan’s syndrome

I. Tazi
  • I. Tazi
  • Hematology Department, Chu Mohamed VI, University Cadi Ayyad, Marrakech, Morocco.
  • Search for this author on:
  • Google Scholar
H. Nafil
  • H. Nafil
  • Hematology Department, Chu Mohamed VI, University Cadi Ayyad, Marrakech, Morocco.
  • Search for this author on:
  • Google Scholar
L. Mahmal
  • L. Mahmal
  • Hematology Department, Chu Mohamed VI, University Cadi Ayyad, Marrakech, Morocco.
  • Search for this author on:
  • Google Scholar


  •  Accepted: 25 January 2011
  •  Published: 28 February 2011

Abstract

The management of Evan’s syndrome remains a challenge and innovative approaches are needed. Initial therapeutic failure, relapses after initial response and refractoriness to treatments are typical. Options for second-line therapy include immunosuppressive drugs, especially cyclosporin or mycophenolate mofetil; vincristine; danazol or a combination of these agents. We report here a long-term remission of Evan’s syndrome obtained with 6-mercaptopurine in a 35-year-old female patient.

 

Key words: 6-Mercaptopurine, Evan’s syndrome, remission.

Copyright © 2024 Author(s) retain the copyright of this article.

This article is published under the terms of the Creative Commons Attribution License 4.0

Back to Vol. 3 No. 2
Back to articles
SUBSCRIBE TO RSS
SUBMIT MANUSCRIPT
CONFERENCES